ASPIRAAspira Pathlab&Diagn

₹60.32-1.07%

Market Cap

₹62.09 Cr

Stock P/E

24.27

ROCE

-18.49%

ROE

-23.34%

Book Value

₹12.32

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Public

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Laggard

Aspira Pathlab & Diagnostics Ltd. is significantly underperforming compared to its peers across various financial metrics, showing no growth, no profitability, and high valuation ratios, making it a laggard in the Hospital & Healthcare Services sector.

Key Points

• Aspira shows zero growth in revenue and EPS across periods.
• All profitability metrics (ROE, ROA, ROCE) are absent for Aspira, indicating no returns.
• Compared to peers, Aspira's PE and PBV ratios are high without corresponding profitability.

Top Performers

Max Healthcare Institute Ltd.

Highest revenue growth YoY (18.49%) and strong profitability with a ROE of 13.47%.

Narayana Hrudayalaya Ltd.

Strong ROE of 24.27%, good revenue growth, and attractive PE ratio.

Global Health Ltd.

Solid revenue growth YoY (21.56%) and a favorable debt-to-equity ratio (0.0968).

Explore

Watchlists

Command Palette